After latest Xarelto setback, J&J, Bayer forge ahead with 5 new trials
This article was originally published in Scrip
Executive Summary
Johnson & Johnson and Bayer are launching five new clinical trials to test their blood thinner Xarelto in people with heart disease and other coronary conditions.